Trials / Completed
CompletedNCT02403271
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Pharmacyclics LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibrutinib | BTK Inhibitor |
| DRUG | Durvalumab | Anti PDL-1 |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2017-08-01
- Completion
- 2017-08-01
- First posted
- 2015-03-31
- Last updated
- 2019-01-03
- Results posted
- 2019-01-03
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02403271. Inclusion in this directory is not an endorsement.